Dual Immunological Checkpoint Blockade for Uveal Melanoma
Mené en Espagne sur 52 patients atteints d'un mélanome de l'uvée de stade métastatique (âge médian : 59 ans), cet essai de phase II évalue l'efficacité, du point de vue de la survie globale à 12 mois, et la toxicité d'un traitement de première ligne combinant nivolumab et ipilimumab
Despite the dramatic progress that has been made in elucidating the complex biology of cancer and translating this knowledge into novel therapeutics, there remain malignancies for which we do not have clearly defined optimal management strategies. Because of the challenges inherent with rare cancer research, 1 this limitation disproportionately affects patients with less common malignancies such as uveal melanoma (UM). UM is a rare subtype of melanoma with an incidence that varies by country and region but ranges between < 1 and > 9 per million persons per year. 2 Although there exist a number of treatment options for the management of metastatic UM, including regional liver-directed therapies and various systemic therapies, no therapy has been proven to meaningfully improve outcomes for these patients, and there remains no therapy approved by the US Food and Drug Administration for this disease. As there is a paucity of randomized trials for this population to guide management recommendations, the pool of data available to guide decision making is largely limited to relatively small single-arm clinical trials and retrospective series.
Journal of Clinical Oncology , éditorial en libre accès, 2020